Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Corning Incorporated (GLW) Price & Performance

Cytokinetics IncTrade
Corning IncorporatedTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Corning Incorporated — how do they compare? Cytokinetics Inc trades at $76.73 (market cap $10.63B), while Corning Incorporated trades at $167.34 (market cap $137.12B). The key difference: Corning Incorporated is far larger — about 12.9× Cytokinetics Inc's market cap, and Corning Incorporated pays a 0.7% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

CYTKGLW
Market Cap
$10.63B$137.12B
Sector
TechnologyTechnology
52-Week High
$87.26$255.79
52-Week Low
$34.31$64.52
Enterprise Value
$10.74B$144.00B
Dividend Yield
0.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Corning Incorporated

Corning (GLW) trades at $157.74, down 4.8% in the last session amid broader market volatility. The stock shows strong fundamental momentum with three consecutive quarterly earnings beats and projected 2026 revenue growth to $17B. Technical indicators are mixed with a neutral overall signal while valuation metrics remain elevated with a P/E of 73.36. Recent analyst upgrades highlight AI infrastructure and optical communications growth potential.

GLW presents a compelling growth story driven by AI data center demand and optical communications expansion, though premium valuation requires flawless execution. Key risks include competitive pressures in photonics and sensitivity to technology spending cycles. With 57% analyst buy ratings and a $193.33 consensus target offering 23% upside, the stock warrants consideration for growth-oriented investors despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Corning Incorporated

Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.

Read more on GLW